Table 1.
Demographic and clinical characteristics of study patients
| Characteristics | Valuesa (n = 49) |
|---|---|
| Age (yr) | 11.5 (4–17) |
| Sex [females, n (%)] | 33 (67.3 %) |
| Weight (kg) | 41 (13.4–119.7) |
| Height (cm) | 146 (95–178) |
| MTX weekly dose (mg) | 13.75 (7.5–20) |
| MTX weekly dose (mg/kg) | 0.31 (0.08–0.67) |
| MTX weekly dose (mg/m2)b | 10.2 (4.1–15.5) |
| Number of medications prescribed | 5 (1–8) |
| Number of side effects recorded | 3 (1–2) |
| Pain scalec | 0.9 (0–7.1) |
| General evaluation scalec | 0.5 (0–8.2) |
| CMAS scored | 51.5 (42–55) |
aValues represent median (range), except where indicated otherwise
bSurface area was calculated using the Mosteller method [59]
cPain scale and general evaluation scores were obtained from the patients’ Childhood Health Assessment Questionnaire
dChildhood Myositis Assessment Scale (CMAS) score was recorded for children with JDM